Developer of immunotherapies through a bispecific antibody intended to developing therapeutics in the area of immuno-oncology. The company's platform offers to develop drug candidates with high anti-tumor potential, superior manufacturability and optimal drug-like properties, enabling biotechnology companies to format antibodies from any pair of monospecific monoclonal antibodies as building blocks, in a timely and cost-effective manner.